Godwin Mary E.
Known title: Senior VP, OperationsCIK: 0001439716
Associated companies
Transaction History
| NAUT | ▲ Buy | Option Exercise | 47,031 | $22K | 9/23/2024 | View on chart |
| NAUT | ▼ Sell | Open Market | 47,031 | $135K | 9/23/2024 | View on chart |
| NAUT | ▲ Buy | Option Exercise | 35,000 | $16K | 9/17/2024 | View on chart |
| NAUT | ▼ Sell | Open Market | 35,000 | $100K | 9/17/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Roth Capital initiates coverage on NAUT with $3.50 target
Roth Capital began tracking Nautilus Biotechnology with a Buy rating and a price target of $3.50. This new analyst note adds to the current consensus, where the average target from two analysts is $4.00. The stock is currently trading within its 52-week range of $0.72 to $4.31.
Roth Capital initiates coverage on NAUT with $3.50 target. Roth Capital began tracking Nautilus Biotechnology with a Buy rating and a price target of $3.50. This new analyst note adds to the current consensus, where the average target from two analysts is $4.00. The stock is currently trading within its 52-week range of $0.72 to $4.31.